All Articles tagged patent

• General
  July 22, 2020 EDT
  PATENTING BLOCKCHAIN: MITIGATING THE PATENT INFRINGEMENT WAR
  Shlomit Yanisky-RavidEdward Kim

  This article, while acknowledging blockchain’s potential, focuses on certain misperceptions that are often associated with the technology.

• General
  December 12, 2018 EDT
  EFFECT OF THE REGULATORY ACCOUNTABILITY ACT OF 2017 ON INTER PARTES REVIEW: A LOOK AT TELEBRANDS CORP., V. TINNUS ENTERS., LLC
  Ashley E. Panek

  This article discusses a specific instance of an inconsistent ruling by the Patent Trial and Appeal Board in Telebrands Corp., v. Tinnus Enters., LLC.

• General
  January 01, 2018 EDT
  AMENDING ALICE: ELIMINATING THEUNDUE BURDEN OF “SIGNIFICANTLY MORE”
  Michael R. Woodward

  Alice Corp. v. CLS Bank runs afoul of Congress's intent in enacting 35 U.S.C. § 101 and should be clarified so district court judges can better interpret patent laws.

• New York Appeals
  March 03, 2012 EDT
  NEW YORK INTELLECTUAL PROPERTY LAW REVIEW
  David P. Miranda

  This Article reviews Second Circuit decisions in the area of intellectual property law and their applicability to New York law and impact beyond the Second Circuit.

• General
  January 01, 2012 EDT
  PATENT REFORM AND BEST MODE: A SIGNAL TO THE PATENT OFFICE OR A STEP TOWARD ELIMINATION?
  Ryan Vacca

  This article proposes and explores several innovative techniques that could be used to add teeth to the seemingly toothless best mode requirement.

• General
  January 01, 2011 EDT
  SECONDARY CONSIDERATIONS: A STRUCTURED FRAMEWORK FOR PATENT ANALYSIS
  Jonathan J. Darrow

  This article brings together the divergent strands of the secondary considerations doctrine into a single, robust framework that might be further developed by future commentators and courts.

• General
  January 01, 2010 EDT
  A SAFE HARBOR FOR DRUGS MADE OFFSHORE: THE FEDERAL CIRCUIT RENDERS THE BOLAR AMENDMENT AVAILABLE IN § 337 ACTIONS IN AMGEN V. U.S. INTERNATIONAL TRADE COMMISSION
  Teige P Sheehan

  This comment articulates the current state of patent law as it pertains to importation and the pharmaceutical industry, in light of Amgen, Inc. v. U.S. Int'l Trade Comm'n.